Sanofi-Aventis Picks Up U.S. Rights to Oral Fludarabine From Antisoma for $65 million

Tue, 05/12/2009 - 4:45am
Antisoma plc has sold the US rights to oral fludarabine, its FDA-approved treatment for chronic lymphocytic leukaemia (CLL), to sanofi-aventis U.S. in exchange for an immediate cash payment of USD 60 million (approximately GBP 40 million) and further payments totalling USD 5 million. Glyn Edwards, CEO of Antisoma, said: "The sale of oral fludarabine roughly doubles our cash resources, and will enable us to pursue all our priority programmes until at least mid-2011, which is well beyond when we expect key phase III results for our leading products, ASA404 and AS1413."

Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.